T. Rogers

Phase I Trial of Irinotecan, Infusional 5-Fluorouracil, and Leucovorin (FOLFIRI) with Erlotinib (OSI-774)

M. Hidalgo, N. Senzer, D. Ramies, 2004, Clinical Cancer Research.

A Phase II Trial of Temozolomide and IFN-α in Patients with Advanced Renal Cell Carcinoma

C. Huff, J. Walczak, M. Carducci, 2004 .

Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly.

J. Verweij, M. Carducci, W. Graveland, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Atrasentan, a n E ndothelin-Recep tor A ntagonist f or Refractory A denocarcinomas: S afety a nd P harmacokinetics

J. Nelson, M. Carducci, R. Donehower, 2013 .

Transarterial Chemoembolization for HCC in Patients With Extensive Liver Transplantation Waiting Times

S. Sontag, J. Brems, M. Borge, 2012, Angiology.

Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics.

J. Nelson, M. Carducci, R. Donehower, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.